Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02401581
Other study ID # 14-PP-07
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2, 2015
Est. completion date June 8, 2021

Study information

Verified date September 2021
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Benign hypertrophy of the prostate (BPH) is the most frequent pathology in the urinary tract of middle-aged men. In recent years, to enable BPH treatment with larger volumes and to reduce the risk of hemorrhage known to be associated to the transurethral resection of prostate treatment, transurethral photovaporisation of the prostate (PVP ) with the GreenLight (GL) XPS 180 W was developed. Therefore, the question arises to maximally reduce the length of catheterization to facilitate outpatient surgical management of prostate adenoma. In the investigators study, the investigators propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia. To this end, the investigators realize a national multicenter prospective study including 300 patients. The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 8, 2021
Est. primary completion date August 21, 2019
Accepts healthy volunteers No
Gender Male
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria: 1. patients with lower urinary tract symptoms (LUTS ) 2. IPSS= 15 despite medical treatment > 1 month if monotherapy or > 3 months if bitherapie OR acute urinary retention ( RAU ) non-medical after the 1st failure to remove the catheter OR acute prostatitis OR macroscopic haematuria of prostatic origin 3. prostate volume > 30 cc by transrectal ultrasonography ; 4. IPSS Qol = 3 has at inclusion ; 5. PSA = 4 ng / ml ; 6. if PSA between 4 and 10 then PSA L/T =25 % or negative PBP <6 months . 7. Accommodation <50 km; 8. company available for the return at home and monitoring first post- operative night . 9. patient sign the informed consent 10. patient covered by social security or other health insurance Exclusion criteria 1. post- voiding residue > 250 cc by suprapubic ultrasound not older than < 45 days 2. prostate volume > 100 cc by transrectal ultrasound not older than 45 days 3. urological antecedents : o urethral stenosis or cervical disease - UTI in progress - SAD patient or self-catheterization - obstructive hydronephrosis + / - renal failure - vesical calculi - cancer of the prostate treated or untreated - bladder tumor associated - Interstitial cystitis ( symptom or biopsy) 4. antecedent of the prostate surgery 5. neurologic bladder ( parkinsonian syndrome , multiple sclerosis , lupus, neuropathy, Diabetic, cauda equina syndrome ) 6. criteria related concomitant medications that can not be stopped at least < 48 hours before PVP with GL XPS 180 W 7. contra indication for outpatient care for medical reason 8. contra indication of a product analgesic according to protocol 9. patient inability to understand and sign the informed consent as well as completing the questionnaires 10. ASA Score > 3 .

Study Design


Intervention

Other:
Catheter
The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).

Locations

Country Name City State
France CHU Brest Urologie Brest
France CH Grasse - urologie Grasse Alpes-maritimes
France CHU Grenoble Grenoble
France CHU Limoges -Urologie - Hôpital Dupuytren Limoges
France APHM - Urologie - Hôpital Conception Marseille Paca
France CHU de Nice - Urologie Nice Alpes-Maritimes
France AP-HP - Urologie Hôpital Tenon Paris Ile De France
France Institut Mutualiste Monsouris urologie Paris Ile De France
France Polyclinique les Bleuets Reims
France CHU Rennes Rennes
France CH privé St Brieuc Saint-Brieuc Cote D'armor
France CHRU Tours Tours Vendée

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary failure rate of a limited catheterization duration of 3 hours post- operative • The failure rate of a limited catheterization duration of 3 hours post- operative is defined by a need of recatheterizatrion within 24 hours post- GL with PVP XPS 180W . The catheterization remains indicated in case of macroscopic hematuria RAU or if no natural urination is possible at three hours post surgery
Secondary Total dose of energy The total dose of energy delivered to the tissue induring the intervention will be expressed and collected by means of the instrumentation of the GL-XPS console. during 24 hours hospitalisation
Secondary The duration of recatherization The duration of recatherization is regarded as the total cumulative duration of catheterization regardless of the number of attempts for removale when it is a failure. The average duration of resondage counts only recatheterizations occurring in the first week which may be considered as due to PVP with GL XPS 180W followed by a shortened catheterization of 3 hours post- operatively . The duration of recatherization is defined from the time when it was done in thefirst week post- operative until urinary recovery during 24 hours hospitalisation
See also
  Status Clinical Trial Phase
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT01177436 - Prostate Cancer Antigen 3 (PCA-3) Gene Project N/A
Completed NCT05082142 - Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) Phase 4
Completed NCT01260129 - Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Phase 4
Completed NCT00771394 - Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Phase 4
Active, not recruiting NCT03630926 - Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Completed NCT02429219 - Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate N/A
Completed NCT01342562 - The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly N/A
Completed NCT00382356 - Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H) N/A
Completed NCT00029822 - Clinical Trial in Males With BPH (Enlarged Prostate) Phase 3
Completed NCT05308017 - Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP N/A
Completed NCT00670306 - Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT00663858 - Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Phase 3
Terminated NCT00449150 - Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Phase 3
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Suspended NCT02533687 - Comparison of Different Energy Sources During TUR-P N/A
Completed NCT00427219 - The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Phase 2
Completed NCT04781049 - Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial N/A
Completed NCT02051036 - Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study N/A
Completed NCT00634608 - Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow N/A